Status: Recruiting
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Participants needed: 31
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: H. Lee Moffitt Cancer Center and Research InstituteUpdated: Sep 28, 2026Locations: 2
Eligibility criteria
HR+ breast cancer to fulfill the requirement of HR+ disease, a breast cancer mus... [+13]
Presence of leptomeningeal disease [+12]